Your browser doesn't support javascript.
loading
Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study.
Sanchez, Jorge; Gonçalves, Elena; Llano, Anuska; Gonzáles, Pedro; Fernández-Maldonado, María; Vogt, Annika; Soria, Angele; Perez, Susana; Cedeño, Samandhy; Fernández, Marco Antonio; Nourikyan, Julien; de Bernard, Simon; Ganoza, Carmela; Pedruzzi, Eric; Bonduelle, Olivia; Mothe, Beatriz; Gòmez, Carmen E; Esteban, Mariano; Garcia, Felipe; Lama, Javier R; Brander, Christian; Combadiere, Behazine.
Afiliación
  • Sanchez J; Centro de Investigaciones Tecnológicas, Biomedicas y Medioambientales, Universidad Nacional Mayor de San Marcos, Lima, Peru.
  • Gonçalves E; Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMIParis), Paris, France.
  • Llano A; IrsiCaixa AIDS Research Institute-HIVACAT, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
  • Gonzáles P; Asociacion Civil Impacta Salud y Educacion, Lima, Peru.
  • Fernández-Maldonado M; Asociacion Civil Impacta Salud y Educacion, Lima, Peru.
  • Vogt A; Clinical Research Center for Hair and Skin Science, Department of Dermatology, Venerology and Allergy, Charité-Universitatsmedizin Berlin, corporate member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Soria A; AP-HP Pitié-Salpêtrière, Paris, France.
  • Perez S; Centro de Investigaciones Tecnológicas, Biomedicas y Medioambientales, Universidad Nacional Mayor de San Marcos, Lima, Peru.
  • Cedeño S; IrsiCaixa AIDS Research Institute-HIVACAT, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
  • Fernández MA; Flow Cytometry Facility, Germans Trias i Pujol Research Institute (IGTP), Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
  • Nourikyan J; AltraBio, Lyon, France.
  • de Bernard S; AltraBio, Lyon, France.
  • Ganoza C; Asociacion Civil Impacta Salud y Educacion, Lima, Peru.
  • Pedruzzi E; Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMIParis), Paris, France.
  • Bonduelle O; Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMIParis), Paris, France.
  • Mothe B; IrsiCaixa AIDS Research Institute-HIVACAT, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
  • Gòmez CE; Fundació Lluita contra la Sida, Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • Esteban M; Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
  • Garcia F; Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
  • Lama JR; Infectious Diseases Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
  • Brander C; Asociacion Civil Impacta Salud y Educacion, Lima, Peru.
  • Combadiere B; IrsiCaixa AIDS Research Institute-HIVACAT, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
Front Immunol ; 11: 586124, 2020.
Article en En | MEDLINE | ID: mdl-33244316
Background: Our previous work has demonstrated the benefits of transcutaneous immunization in targeting Langerhans cells and preferentially inducing CD8 T-cell responses. Methods: In this randomized phase Ib clinical trial including 20 HIV uninfected volunteers, we compared the safety and immunogenicity of the MVA recombinant vaccine expressing HIV-B antigen (MVA-B) by transcutaneous and intramuscular routes. We hypothesized that the quality of innate and adaptive immunity differs according to the route of immunization and explored the quality of the vector vaccine-induced immune responses. We also investigated the early blood transcriptome and serum cytokine levels to identify innate events correlated with the strength and quality of adaptive immunity. Results: We demonstrate that MVA-B vaccine is safe by both routes, but that the quality and intensity of both innate and adaptive immunity differ significantly. Transcutaneous vaccination promoted CD8 responses in the absence of antibodies and slightly affected gene expression, involving mainly genes associated with metabolic pathways. Intramuscular vaccination, on the other hand, drove robust changes in the expression of genes involved in IL-6 and interferon signalling pathways, mainly those associated with humoral responses, and also some levels of CD8 response. Conclusion: Thus, vaccine delivery route perturbs early innate responses that shape the quality of adaptive immunity. Clinical Trial Registration: http://ClinicalTrials.gov, identifier PER-073-13.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas Virales / Vacunas contra el SIDA Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Humans Idioma: En Revista: Front Immunol Año: 2020 Tipo del documento: Article País de afiliación: Perú Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas Virales / Vacunas contra el SIDA Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Humans Idioma: En Revista: Front Immunol Año: 2020 Tipo del documento: Article País de afiliación: Perú Pais de publicación: Suiza